AbbVie Inc. (ABBV)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-26, AbbVie traded at $286.74, and FairStock calculated a P/E of 80.77, EV/EBITDA of 29.20 and FCF yield of 3.6%. That is not a Graham bargain. The company has real scale: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $17.0B, net income $3.6B and diluted EPS $2.03. But the path is uneven: fiscal Q1 2026 net income was $695.0M, and fiscal Q3 2025 net income was $186.0M. For FY2025, filed revenue was $61.2B versus $56.3B in FY2024, while net income was $4.2B versus $4.3B. So revenue is growing, but profit has not kept pace. The TTM free cash flow of $18.2B is meaningful, and a 2.41% dividend yield with beta of 0.23 suggests defensiveness. Still, FairStock's Lynch category is Slow Grower, citing shrinking profit at -1.7% a year over five years and revenue at 6.0%. The balance sheet signals are distorted: P/B of -125.12, ROE of 6225% and D/E marked N/A make book-based measures nearly useless, while an Altman Z of 2.19 and Piotroski F-Score of 7/9 show some resilience, not a fortress. A PEG of 0.28 could look attractive if earnings normalize, but the high P/E and EV/EBITDA already price in recovery. I would want a clearer five-year profit trend and a wider margin of safety before calling this cheap.

In plain English: AbbVie makes medicines for immune diseases, blood cancers, and other cancers. The business brings in large sales and cash, but recent profits have been uneven and the share price looks expensive compared with those profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer